Back to Newsroom

Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies

Gaithersburg, MD – October 15, 2014 – Novavax, Inc. (Nasdaq: NVAX) a clinical-stage
biopharmaceutical company focused on the discovery, development and commercialization of
recombinant nanoparticle vaccines and adjuvants, today announced that its RSV F-protein
nanoparticle vaccine candidate (RSV F Vaccine) evoked a polyclonal antibody response to
antigenic site II, the same site targeted by the monoclonal antibody palivizumab (Synagis®),
resulting in protection from an RSV challenge in an animal model. Researchers at Novavax
reported these findings in an online paper published by Vaccine titled: “An insect cell derived
respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and
protects against RSV challenge in cotton rats by active and passive immunization.”

Click here to read more